Alexion Pharmaceuticals, Inc. ALXN today announced that
researchers presented new data from a long-term follow-up study
evaluating the effectiveness and safety of Soliris®
(eculizumab) in preventing thrombotic microangiopathy (TMA)—the
formation of blood clots in small blood vessels throughout the body—in
patients with atypical hemolytic uremic syndrome (aHUS), a genetic,
chronic, ultra-rare disease associated with vital organ failure and
premature death.1,2,3 In this observational study,
researchers reported a 74 percent lower TMA event rate with ongoing
Soliris treatment with labeled dosing compared with discontinuation of
Soliris therapy.4 These data were presented at the 2015
American Society of Nephrology (ASN) Annual Meeting in San Diego.
"Patients with aHUS face a
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in